FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000020947> ?p ?o ?g. }

• W3000020947 abstract "ABSTRACT Purpose Tivozanib hydrochloride is a potent, selective, long half-life inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. Inhibition of VEGF-driven angiogenesis is known to reduce vascularization and tumor growth. Currently, sunitinib is most commonly used as first-line treatment in patients with mRCC. Previous Phase II and Phase III studies have demonstrated the promising efficacy and safety of tivozanib in patients with mRCC. The primary objective of this study is to compare patient preferences for tivozanib or sunitinib. Secondary objectives include assessing overall safety and tolerability, frequency of dose modifications, and quality of life in patients treated with tivozanib and sunitinib.Study design: This Phase II, randomized, double-blind, multinational, crossover study will compare the preference of mRCC patients for tivozanib or sunitinib as treatment for metastatic disease. Recruitment of 160 patients is planned. Patients will be randomized to tivozanib 1.5 mg/d for 12 weeks (wks) (Cycle = 3 wks on, 1 wk off) or sunitinib 50 mg/d for 12 wks (Cycle = 4 wks on, 2 wks off). After a washout period, patients will cross over to the alternate treatment (sunitinib or tivozanib). Methods After 12 wks of treatment, tumor response will be assessed using Response Evaluation Criteria In Solid Tumors (version 1.1). Patients are expected to cross over to the second treatment for 12 wks; however patients with a significant clinical response (defined as >50% tumor reduction or complete response for non-measurable disease) will be given the option to continue the first treatment if they choose. Patients with Grade 3/4 adverse events may have a dose interruption of ≤2 wks to manage toxicities, after which they may continue at the same or reduced dose; dose reductions to 1.0 mg/d for tivozanib and 37.5 mg/d for sunitinib will be allowed. After the second 12-wk period, patients' drug preferences, based on a questionnaire, and their tumor response will be assessed and reviewed prior to a final tumor assessment. Conclusion The double-blind design of this study will enable comprehensive assessment of patient preference for tivozanib and sunitinib as treatment for mRCC. Disclosure B. Escudier: Board Membership:Pfizer, GSK, Bayer, AVEO, Novartis Consultancy: Pfizer, GSK, Bayer, Payment for lectures, service on spkrs bureaus:Pfizer, Novartis Payment for development of educational presentations: Pfizer, GSK, Bayer, AVEO, Novartis. L. Steelman: Current Employment: AVEO with stock options Employment: Novartis until 8/11 Employment: ARIAD until 11/09. D. Cesic: AVEO Pharmaceuticals employee with stock options. A. Berkenblit: AVEO Pharmaceuticals employee with stock options" @default.
• W3000020947 created "2020-01-23" @default.
• W3000020947 creator A5021160908 @default.
• W3000020947 creator A5049672639 @default.
• W3000020947 creator A5065124671 @default.
• W3000020947 creator A5091807722 @default.
• W3000020947 date "2012-09-01" @default.
• W3000020947 modified "2023-09-26" @default.
• W3000020947 title "Patient Preference for Tivozanib Hydrochloride or Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Taurus Study" @default.
• W3000020947 doi "https://doi.org/10.1016/s0923-7534(20)33360-3" @default.
• W3000020947 hasPublicationYear "2012" @default.
• W3000020947 type Work @default.
• W3000020947 sameAs 3000020947 @default.
• W3000020947 citedByCount "0" @default.
• W3000020947 crossrefType "journal-article" @default.
• W3000020947 hasAuthorship W3000020947A5021160908 @default.
• W3000020947 hasAuthorship W3000020947A5049672639 @default.
• W3000020947 hasAuthorship W3000020947A5065124671 @default.
• W3000020947 hasAuthorship W3000020947A5091807722 @default.
• W3000020947 hasBestOaLocation W30000209471 @default.
• W3000020947 hasConcept C126322002 @default.
• W3000020947 hasConcept C126894567 @default.
• W3000020947 hasConcept C143998085 @default.
• W3000020947 hasConcept C197934379 @default.
• W3000020947 hasConcept C2777472916 @default.
• W3000020947 hasConcept C2778375690 @default.
• W3000020947 hasConcept C2779490328 @default.
• W3000020947 hasConcept C71924100 @default.
• W3000020947 hasConceptScore W3000020947C126322002 @default.
• W3000020947 hasConceptScore W3000020947C126894567 @default.
• W3000020947 hasConceptScore W3000020947C143998085 @default.
• W3000020947 hasConceptScore W3000020947C197934379 @default.
• W3000020947 hasConceptScore W3000020947C2777472916 @default.
• W3000020947 hasConceptScore W3000020947C2778375690 @default.
• W3000020947 hasConceptScore W3000020947C2779490328 @default.
• W3000020947 hasConceptScore W3000020947C71924100 @default.
• W3000020947 hasLocation W30000209471 @default.
• W3000020947 hasOpenAccess W3000020947 @default.
• W3000020947 hasPrimaryLocation W30000209471 @default.
• W3000020947 hasRelatedWork W1838582108 @default.
• W3000020947 hasRelatedWork W2075684117 @default.
• W3000020947 hasRelatedWork W2104113125 @default.
• W3000020947 hasRelatedWork W2115966993 @default.
• W3000020947 hasRelatedWork W2170339563 @default.
• W3000020947 hasRelatedWork W2187011604 @default.
• W3000020947 hasRelatedWork W2244715621 @default.
• W3000020947 hasRelatedWork W2248764108 @default.
• W3000020947 hasRelatedWork W2570719551 @default.
• W3000020947 hasRelatedWork W2590180656 @default.
• W3000020947 hasRelatedWork W2806146840 @default.
• W3000020947 hasRelatedWork W2893778816 @default.
• W3000020947 hasRelatedWork W2905004070 @default.
• W3000020947 hasRelatedWork W2910644531 @default.
• W3000020947 hasRelatedWork W2954954143 @default.
• W3000020947 hasRelatedWork W2967350775 @default.
• W3000020947 hasRelatedWork W2978790273 @default.
• W3000020947 hasRelatedWork W2996164021 @default.
• W3000020947 hasRelatedWork W3030472743 @default.
• W3000020947 hasRelatedWork W3093923068 @default.
• W3000020947 isParatext "false" @default.
• W3000020947 isRetracted "false" @default.
• W3000020947 magId "3000020947" @default.
• W3000020947 workType "article" @default.